Team:Shenzhen SFLS/Investigation

;

Fig.1
The 10 leading causes of death worldwide in 2011. COPD, chronic obstructive pulmonary disease.
Generations of scientists devoted their efforts to fighting with cancer.
However, besides continuously developing treatment thechnology,
people’s well cognition on the disease is also required for fighting against the disease.
To observe public cogniton on cancer and cancer therapy,
we documented our survey on our Wechat Public Platform,
an online public platform, and received feedback of an amount of over 600 . The results analyzed are printed below.

Fig. 2 & Fig.3
Our survey conducted among public
Via: We-chat Public Platform

Fig. 4
The feedback of public cognition on cancer

Fig.5
The feedback of public cognition on cancer therapy
As the results shown, when asked about cancer, most people remain knowing "not so much" or "almost nothing at all". And only 19% of the people surveyed know about technologies beside the three main treatment methods(Chemotherapy, Radiotherapy, Surgical Treatment), such as targeted therapy and immunological therapy which may perform more promisingly in future application.

P.S. Therefore, we developed Stage 3, introducing the frontier technologies in cancer treatment field to popularize knowledge of cancer and cancer to the public.

Clinical Application of immunological cancer therapies
------Stage 2
Aiming at looking into the application landscape of cancer therapies, especially the immunological therapies which is related closely to our project, we conduct a survey in two hospitals.
By conducting the survey, we collected information about the application frequency of different therapies in treating patients in different stages.

Fig.6
Application Frequency of different therapiesin different stages in 2014
In Shenzhen Renmin Hospital

Fig.7 Application Frequency of different therapies in different stages in 2014
In Shenzhen Second Renmin Hospital
As shown in Fig.4 and Fig.5, Surgical treatment and Chemothrapy are most frequently used methods in cancer therapy. The former is applied in early stage primarily and the latter is primarily applied in Middle Stage and Final Stage, while immunological treatment methods, which we take Monoclonal Antibody Drug as an example of, are mostly used as helpers to the two therapies mentioned above.

We interviewed Doctor Xianming Li who is the Chief of Tumor Radiotherapy Department in Shenzhen Renmin Hospital. Together, we discussed about the major factors which decide the current status of the application of immunological therapies and the view on cancer therapy development.
Doctor Li suggested that the immunological therapies currently developed perform well in accuracy. But most of them kill tumor cells less directly compared with surgical treatment and sometimes less aggressive compared with chemotherapy. As a result, immunological methods are mostly used before or after surgical treatments or chemotherapy to enhance the effect.
Talking about ADCs, he also shared with us the experience of applying ADCs like drugs to treating a kind of as clinical trails. The treatment turned out to be a failure however due to the uncontrolled high toxicity of the durgs conjugated. Accordingly, Doctor Li pointed out that how to control the toxicity of drugs during drug delivering process and how to reduce undesirable immune system reponses are the two cure problems remained to be solved.
When asked about his view on the future prospects of biological cancer therapy, Doctor Li used "absolutely promising" to express his opinion and he also gave suggestions on us choosing effector molecule in our project.

Fig.8 Doctor Xianming Li--- the Chief of Tumor Radiotherapy Department in Shenzhen Renmin Hospital